Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease
22-Jul-2015 -
Biotie announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease (PD) experiencing levodopa related end-of-dose "wearing-off".The Phase 3 study (TOZ-PD) is a randomized, double-blind, placebo ...
Parkinson's disease
phase III studies
tozadenant